Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
Key Highlights
- ➤RFD4-Proteina open model debuts for programmable protein design and search
- ➤Siemens Healthineers collaboration targets adaptive radiotherapy with agentic and robotic intelligence
- ➤BioNeMo platform powers scientific agents connecting drug design and autonomous laboratories
- ➤NVIDIA open models support hospital operations and specialized-care access across Europe
Expert Statements
Kimberly Powell, Vice president of healthcare at NVIDIA
“Agentic and physical AI are opening new possibilities across medicine, from designing proteins and powering autonomous laboratories to improving personalized cancer care”
Kimberly Powell, Vice president of healthcare at NVIDIA
“Together with healthcare and life science leaders, we’re accelerating scientific discovery and advancing more precise, accessible care around the world.”
David Baker, 2024 Nobel Laureate in chemistry and director of the Institute for Protein Design at the University of Washington
“We are moving from an era of discovering the proteins nature has made to one in which we can design entirely new ones,”
David Baker, 2024 Nobel Laureate in chemistry and director of the Institute for Protein Design at the University of Washington
“RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides.”
David Baker, 2024 Nobel Laureate in chemistry and director of the Institute for Protein Design at the University of Washington
“Making the model open will allow researchers around the world to build on these capabilities and pursue solutions once beyond the reach.”
Arthur Kaindl, Head of Varian, the Siemens Healthineers cancer-care business
“Adaptive radiotherapy is built on a single principle: treatment should adapt to the patient, not the other way around,”
Arthur Kaindl, Head of Varian, the Siemens Healthineers cancer-care business
“We’ve made important advances in precision and adaptation — most recently, with the launch of the Accela system.”
Arthur Kaindl, Head of Varian, the Siemens Healthineers cancer-care business
“Our collaboration with NVIDIA builds on that progress, exploring how AI and real-time computing could give clinicians greater speed and insight to make informed decisions, adapt treatment with greater confidence and deliver personalized care to more patients.”
News Summary: * NVIDIA and the UW Medicine Institute for Protein Design debut RFD4-Proteina, a new open model that combines programmable protein design with search capabilities, unlocking new frontiers in biology. * Siemens Healthineers is advancing the next generation of adaptive radiotherapy, using NVIDIA intelligence to increase access to life-saving cancer care with agentic co-planning, patient-specific simulation and robotic control. * Automata, Benchling, Biolevate, Boltz, Danaher, Hologen and Therna Biosciences are using the NVIDIA BioNeMo open platform to develop scientific agents that connect drug design, autonomous laboratories and biological discovery, helping researchers move from hypothesis to experiments faster. BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) -- GTC Berlin—NVIDIA today announced collaborations with leading global healthcare and research organizations to advance protein design — including through a newly released open model, RFD4-Proteina — accelerate drug discovery and bring greater precision to cancer care.
Get started
Create a free account to read the full story.